Breaking Down the TRAILBLAZER-ALZ 2 Trial

In this episode, we explore when and why long-acting injectable antipsychotics (LAIs) should be considered for patients with schizophrenia, covering approved indications, ideal candidate profiles, and the critical role of shared decision-making in treatment planning. Faculty: Bri ...  Show more

In this episode, we explore a striking new Nature study suggesting that lithium deficiency may play a central role in the onset of Alzheimer's disease. Could a simple, overlooked supplement be the key to prevention? Dr. Scott Beach unpacks the science, the promise, and the import ...  Show more

In this episode of our pharmacology podcast, we take a deep dive into the pharmacology of levomilnacipran (Fetzima), a unique serotonin-norepinephrine reuptake inhibitor (SNRI) approved for the treatment of major depressive disorder (MDD) in adults. Designed for pharmacy students ...  Show more

This episode is a conversation with Dr. Lucette Cysique about long COVID. We discuss terminology, symptom profiles, epidemiology, biological mechanisms, psychological and sociocultural factors, overlap with chronic fatigue syndrome, overlap with functional ne ...

As I've been researching and writing Boundless 2.0, I've found myself reevaluating many of the health and fitness strategies that I previously endorsed.In this episode, prepare to have your perspective challenged as I discuss some of the significant shifts in thinking I've underg ...  Show more

Sam Harris speaks with Dr. Jennifer Mitchell and Dr. Sarah Abedi about recent developments in research on psychedelics. They discuss the history of this research and the war on drugs, recent setbacks in the FDA approval process, MDMA as a treatment for post-traumatic ...